Using two independent breast cancer patient‐derived tumor xenograft (PDX) panels, we assessed the antitumor activity of three PARPi and showed the potential of an immunostaining assay of the HRR protein RAD51 to predict PARPi sensitivity. This evidence concerns the gene RAD51 and breast carcinoma.